Yarrow Bioscience Inc(YARW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -23.46 | Insider Own | 10.87% | Shs Outstand | 9.4M | Perf Week | -2% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 8.4M | Perf Month | -29.7% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -16 | Inst Own | 22.46% | Short Float | 2.25% | Perf Quarter | -22.99% |
| Income | -0.02B | P/S | 385.38 | EPS this Y | - | Inst Trans | 37.51% | Short Ratio | 2 | Perf Half Y | 8.53% |
| Sales | 0.00B | P/B | 0.59 | EPS next 5Y | -29.18% | ROA | -55.24% | Short Interest | 0.19M | Perf YTD | 19.77% |
| Book/sh | 33.01 | P/C | 8.07 | EPS past 3/5Y | -39.77% 66.27% | ROE | -61.93% | 52W High | -55.73% ($44.28) | Perf Year | 98.68% |
| Cash/sh | 2.43 | P/FCF | - | Sales past 3/5Y | 6.12% -51.39% | ROIC | -84.8% | 52W Low | 116.58% ($9.05) | Perf 3Y | -73.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 48.11% | Gross Margin | 95.23% | Volatility(W/M) | 8.22% 9.07% | Perf 5Y | -96.61% |
| Dividend TTM | - | EV/Sales | 337.61 | Sales Y/Y TTM | 1.26% | Oper. Margin | -4134.65% | ATR (14) | 2 | Perf 10Y | - |
| Dividend Ex-Date | 2026/7/24 | Quick Ratio | 15.26 | EPS Q/Q | 47.92% | Profit Margin | -3881.54% | RSI (14) | 38.09 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.26 | Sales Q/Q | 40.58% | SMA20 | -5.56% ($20.75) | Beta | 2.07 | Target Price | $57 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -30.36% ($28.14) | Rel Volume | 1.52 | Prev Close | $20.17 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 80.55% - | SMA200 | -9.51% ($21.66) | Avg Volume(3M) | 0.09M | Price | $19.6 |
| IPO | 2018/1/25 | Option/Short | No/Yes | Trades | 2023 | Volume | 143,786 | Change | -2.83% |
� This is a clinical-stage biotech company developing antibody therapeutics aimed at thyroid autoimmune diseases. It is focused on monoclonal antibody candidates that target the thyroid-stimulating hormone receptor, with clinical development geared toward treating Graves' disease and thyroid eye disease. The company remains a research-and-development-driven organization with no product revenue yet.
Over the past 1 year, roughly in the middle
56% below its 1-year high.
Traded more than usual. That is 152% of its average volume.
YARW has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -29.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $38,538. Peers typically go for $1,138.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.5%.
Tap to view numbers
It ranks #305 of 594 in the industry
Based on market cap of $185M.
CGEN#303 Compugen Ltd $186M PER 5.3 
WHWK#304 Whitehawk Therapeutics Inc $185M PER - YARW#305 Yarrow Bioscience Inc $185M PER - 
TRDA#306 Entrada Therapeutics Inc $184M PER - 
BCYC#307 Bicycle Therapeutics Plc ADR $183M PER - 
FAQ
What kind of company is YARW?
YARW belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of YARW?
The market cap of YARW is approximately $185M, ranking 4,068 within its sector.
What is the 52-week high and low for YARW?
YARW has recorded a 52-week high of $44.28 and a low of $9.05.
